首页> 外文期刊>BMC Cancer >The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
【24h】

The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases

机译:局部控制局部对整体癌肝脏肺转移后整体存活的影响:388例转移患者的组合分析

获取原文
       

摘要

The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer. The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS. Three hundred eighty-eight patients with 500 metastatic lesions (lung n?=?209, liver n?=?291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1?months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9?months in all patients and 25.4?months versus 30.6?months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10?months indicating better survival with LC. In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of ?12?months.
机译:该分析的目的是模拟局部对照(LC)对用直肠癌肝脏或肺转移患者治疗的患者的整体存活(OS)的影响。该分析基于来自德国和瑞士27个中心的两种回顾性SBRT数据库的汇总数据。仅考虑患有来自结肠直肠癌转移的患者,以避免组织学作为混杂因素。使用疾病 - 死亡模型来模拟LC和OS之间的关系。三百八十八名患者500例转移性病变(肺部α=Δ209,肝脏N?= 291)被纳入并分析。当地复发评估的中位后续时间为12.1?几个月。九十九患者112例病灶经历了局部失败。这些患者中的七十一位在局部失败后死亡。中位生存时间为27.9?在所有患者中为27.9个月,25.4个月为30.6个月,患者患者患者和没有局部失败后的患者。在局部失败后死亡的基线风险超过了死亡的基线风险,而不在10?月份的局部失败,表明与LC更好地生存。在CRC患者肺或肝转移患者中,我们的研究结果表明,通过在预计OS估计的患者中使用SBRT达到转移性疾病控制来改善长期OS,其>?12个月的估计。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号